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We addressed the question how long salivary oxytocin levels remain elevated after
intranasal administration, and whether it makes a difference when 16 or 24 IU of oxytocin
administration is used. Oxytocin levels were measured in saliva samples collected from
46 female participants right before intranasal administration (at 9:30 a.m.) of 16 IU (n=18)
or 24 IU (n=10) of oxytocin, or a placebo (n=18), and each hour after administration, for
7 h in total. Oxytocin levels did not differ among conditions before use of the nasal spray.
Salivary oxytocin levels in the placebo group showed high stability across the day. After
oxytocin administration oxytocin levels markedly increased, they peaked around 1 h after
administration, and were still significantly elevated 7 h after administration. The amount
of oxytocin (16 or 24 IU) did not make a difference for oxytocin levels. The increase of
oxytocin levels for at least 7 h shows how effective intranasal administration of oxytocin
is. Our findings may raise ethical questions about potentially persisting behavioral effects
after participants have left the lab setting. More research into the long-term neurological
and behavioral effects of sniffs of oxytocin is urgently needed.
Keywords: oxytocin, intranasal administration, saliva, 16 IU, behavioral effects, healthy female volunteers, daily
oxytocin curve, ethics
INTRODUCTION
Intranasal oxytocin (OT) administration is used in numerous
experimental studies to investigate the role of this neuropep-
tide in neural activation, information processing, and behavior
(e.g., Insel, 1992; Carter, 2003; Parker et al., 2005; Feldman et al.,
2007; Campbell, 2008; De Dreu et al., 2010; Naber et al., 2010; for
reviews see Heinrichs et al., 2009; MacDonald and MacDonald,
2010; Bartz et al., 2011; Galbally et al., 2011; for a meta-analysis
see Van IJzendoorn and Bakermans-Kranenburg, 2012). How-
ever, surprisingly little is known about the long-term effects of
intranasal OT administration, and what minimal dose of OT
might still be effective. Although 24 IU of OT seem to be standard
in psychopharmacological experiments (with a range of 16–48
IU, see MacDonald et al., 2011; Van IJzendoorn and Bakermans-
Kranenburg, 2012) there is no empirical evidence suggesting that
lower doses would be less effective. Here we examine the influence
of 16 or 24 IU OT on salivary OT levels in the course of the day in
a sample of healthy female participants.
In the first study on levels of salivary OT after intranasal
administration, Huffmeijer et al. (2012) found that OT lev-
els remained highly elevated for more than 2 h. The study
included 57 female participants who provided saliva samples
right before, approximately 1 14 h, and approximately 2
1
4 h after
intranasal administration of 16 IU of OT or a placebo, in a double-
blind, within-subjects design. Average levels of OT did not differ
between conditions at baseline, markedly increased after 16 IU OT
administration, and were still strongly elevated after 2 14 h. Using
a double-blind placebo-control within-subject design, Weisman
et al. (2012) administered 24 IU OT or placebo 1 week apart to ten
individuals (five females). They found strongly increased salivary
OT levels 15 min after intranasal OT administration and OT levels
remained high across the whole 4 h period that assessments took
place.
The studies conducted thus far did not examine the effects of
intranasal administration of OT after the end of a regular exper-
imental session. In both studies levels of salivary OT were still
highly elevated at the end of data-collection, after more than 2 h
with 16 IU (Huffmeijer et al., 2012) and after 4 h with 24 IU
(Weisman et al., 2012). Here we examine whether 16 and 24 IU
doses of OT lead to similarly elevated levels of salivary OT, and
we assess whether OT levels go down to baseline within 7 h after
administration.
MATERIALS AND METHODS
PARTICIPANTS
A total of 46 healthy female undergraduate students, aged 18–
27 years (M = 19.77, SD= 1.53), without children of their own,
took part in the study. Exclusion criteria were pregnancy, and use
of steroidal or any other interfering medications. All participants
were non-smokers and had not used any recreational drugs for at
least 6 months before the experiment. Participants reported not
having any current or past neurological or psychological disor-
ders. The vast majority (90%) of the participants reported that
they were in the luteal phase of their menstrual cycle. Their use of
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oral contraceptives was recorded in order to control for its influ-
ence on OT levels. The study was approved by the ethics committee
of the Leiden University Medical Center.
DESIGN AND PROCEDURE
Participants were asked to come to the laboratory for participa-
tion in an experimental session lasting about 2 h (to be reported
elsewhere), and to stay around for 7 h in order to provide hourly
saliva samples. The experimental task included a paradigm with
happy and sad baby faces to be rated for, e.g., attractiveness (see
Parsons et al., 2011). To minimize influences of diurnal variations
in OT levels, all sessions started at 09:00 a.m. and ended between
16:30 and 17:00 p.m. with the collection of the 8th saliva sample.
Participants were instructed to abstain from alcohol and excessive
physical activity during the 24 h before the start of the session, and
from caffeine on the day the session took place. Informed consent
was obtained at the beginning of the session. Participants were
not informed about the potential effects of OT under investiga-
tion, only about the possible side-effects they might experience (as
was required by the ethics committee).
At the start of the session, a saliva sample was collected to
assess baseline OT level, and participants completed a question-
naire. The participants then were asked to self-administer nasal
spray containing either 16 IU (n= 18) or 24 IU (n= 10) of OT, or
saline as placebo (n= 18) in a double-blind design in the presence
of the experimenter. Thereafter, the participants provided another
saliva sample every hour until a total of eight samples was reached.
Participants were unable to discern whether they had taken active
drug or placebo when asked for at the end of the testing session.
Oxytocin nasal spray
Oxytocin (Syntocinon®,OPG Groothandel,Oss,The Netherlands)
was self-administered by spraying three puffs per nostril, each puff
containing 0.067 ml (2.7 IU) for the 16 IU condition and 0.1 ml
(4 IU) for the 24 IU condition The concentration of the oxytocin
nasal spray was the same for 16 and 24 IU, with higher volumes
used to deliver the higher dose.
Salivary OT
For each sample at least 1 ml of unstimulated saliva was collected
into cryotubes using the passive drool method. Samples were
immediately frozen and were stored at −20˚C until batch assay.
Level of OT in saliva was assayed using a commercially available kit
as per the method previously described (Holt-Lunstad et al., 2008;
Grewen et al., 2010). Prior to the enzyme immunoassay proce-
dure, in keeping with the manufacturer’s strong recommendation,
an extraction step was performed based on instructions accom-
panying the EIA kit available in February 2011 (ADI-900-153,
Enzo Life Science, Plymouth Meeting, PA, USA). The result of this
extraction was to concentrate the sample 3.2 times, increase preci-
sion, and reduce matrix interference. OT extraction efficiency was
94%, which was determined by spiking with a known amount of
hormone and extracting this known amount along with the other
samples. OT levels in extracted saliva were then quantified using
the OT EIA, in which the endogenous OT hormone competes with
added OT linked to alkaline phosphatase for OT antibody binding
sites. After overnight incubation at 4˚C, the excess reagents were
washed away and the bound OT phosphatase was incubated with
substrate. After 1 h this enzyme reaction, which generates a yel-
low color, was stopped and the optical density (OD) was read on
a Sunrise plate reader (Tecan, Research Triangle Park, NC, USA).
The intensity of the color at 405 nm is inversely proportional to
the concentration of OT. The hormone content (in pg/ml) was
determined by plotting the intensity of OD of each sample against
a standard curve. Following correction for extraction, the lower
limit of sensitivity was 1.0 pg/ml. Less than 3% of the samples
fell below the lower level of sensitivity. These values were subse-
quently replaced with the lowest detectable level of 1.0 pg/ml. The
intra- and inter-assay coefficients of variation were 7.56 and 8.20%
respectively. The manufacturer reports that cross-reactivity with
similar mammalian neuropeptides is less than 1%.
Missing data of individuals in the OT conditions were esti-
mated using curve fitting of OT levels across the remaining time
points using a logarithmic function. Missing data of subjects in
the placebo condition were estimated with curve fitting on the
basis of a linear function. Two different functions were used since
they showed optimal fit in the two respective conditions (OT and
placebo). Only two participants showed two missing data points;
nine participants missed one data point.
STATISTICAL ANALYSES
Statistical analyses were performed using SPSS statistics 19 soft-
ware. Pearson correlations were computed between OT levels
across all time points in order to examine stability of the salivary
assessments. To test whether OT levels in saliva increased after
intranasal OT administration, a repeated measures GLM analy-
sis was performed with condition (placebo vs. 16 IU OT vs. 24
IU OT) as between-subjects factor, and time (baseline to 7 h after
administration) as within-subjects factor. To control for a poten-
tial influence of the use of oral contraceptives (used vs. not used)
on OT levels, this variable was included as additional (between-
subjects) factor in a second GLM analysis. Greenhouse–Geisser
corrections were performed when necessary.
RESULTS
Mean OT levels and correlations among OT levels across time
points are presented in Table 1. Stability of OT in the placebo
group was considerable; baseline values correlated 0.32–0.76 with
OT levels later in the day. Stability in the OT group (16 and 24 IU
combined) was more limited to adjacent time points (see Table 1).
Repeated measures analysis of OT levels in the placebo group
showed a significant effect of time,F(3.66, 62.14)= 7.14, p< 0.01,
η2= 0.30. A significant increase between baseline and 1 h later
(p= 0.045) was followed by significant decreases between 2 and
3 h after baseline (p= 0.026) and between 4 and 5 h after baseline
(p= 0.022), see Figure 1A.
Including the two OT conditions in the analysis, we found
a significant interaction between time and condition, F(2.54,
54.49)= 5.20, p= 0.005, η2= 0.20. Baseline OT levels were simi-
lar for the three groups, F(2, 45)= 0.28, p= 0.754, but at all time
points after administration of either placebo or oxytocin (16 or 24
IU) participants in the oxytocin conditions showed much higher
levels of salivary OT, see Figure 1B. Increases in mean OT levels
were tenfold to hundredfold compared to the placebo condition,
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Table 1 | Salivary oxytocin levels (M, SE) up to 7h after intranasal administration and stability of OT levels over the day.
Time Placebo n=18
M (SE)
16 IU n=18
M (SE)
24 IU n=10
M (SE)
Correlations (placebo under diagonal,
combined OT groups above diagonal)
Baseline 1h 2h 3h 4h 5h 6h 7h
Baseline 2.77 (0.65) 2.44 (0.58) 2.60 (0.82) – 0.19 −0.04 −0.16 −0.21 −0.21 −0.22 0.12
1 h 3.88 (0.91) 446.56 (105.26) 157.36 (49.76) 0.32 – 0.77 0.56 0.24 −0.15 0.03 0.28
2 h 4.16 (0.98) 225.50 (53.15) 136.89 (43.29) 0.76 0.55 – 0.56 0.38 −0.02 0.06 0.24
3 h 3.27 (0.77) 100.40 (23.66) 57.71 (18.25) 0.64 0.37 0.79 – 0.59 −0.06 0.10 0.30
4 h 3.34 (0.79) 35.98 (8.48) 72.06 (22.79) 0.68 0.52 0.84 0.77 – 0.21 0.32 0.68
5 h 2.77 (0.65) 43.85 (10.34) 53.75 (17.00) 0.65 0.35 0.87 0.89 0.82 – 0.51 0.28
6 h 2.39 (0.56) 34.02 (8.02) 26.28 (8.31) 0.56 0.20 0.74 0.63 0.88 0.75 – 0.38
7 h 2.56 (0.60) 15.48 (3.65) 23.55 (7.45) 0.42 0.45 0.63 0.71 0.67 0.69 0.56 –
Significant correlations (p<0.05) in bold.
see Table 1. The effect had not faded out 7 h after administration,
and at this point in time the difference was still significant, F(2,
45)= 7.15, p= 0.002.
The effects of 16 and 24 IU oxytocin were similar. There was
no significant interaction between time and condition (16 IU vs.
24 IU), F(1.27, 32.95)= 2.06, p= 0.16, η2= 0.07, and none of the
time points showed a significant difference in OT level between
participants in the 16 IU condition and participants in the 24 IU
condition. At 1 h after administration the difference was maximal
(p= 0.08), but the higher OT levels were found in the 16 IU group.
Including use of oral contraceptives in the analyses did not
change any of the results.
DISCUSSION
Levels of salivary OT increased markedly after intranasal
OT administration and remained elevated up to 7 h after
administration, whereas in the placebo condition salivary
OT remained at a consistently low level. Seven hours after
administration the level of OT had not yet returned to baseline;
in fact it was still six to tenfold higher than OT levels observed in
the placebo condition. The lower dose of 16 IU OT did not show
weaker effects over the day, if anything it tended to elevate the
initial salivary OT levels more than the 24 IU dose.
In the placebo condition salivary OT levels were highly corre-
lated over time, indicating an impressive individual stability of OT
levels over the day. The increase in salivary OT between 1 and 2 h
after placebo administration may be related to the experimental
tasks, which included exposure to pictures of happy and sad baby
faces (Parsons et al., 2011).
Elevated levels of salivary OT up to 7 h after administration are
unlikely to support the idea that this would only result from move-
ment of mucus from the nasal cavities back into the mouth, rather
than reflect changes of OT levels in the brain that in several well-
controlled oxytocin experiments using fMRI (Baumgartner et al.,
2008; Riem et al., 2011, 2012) seem for example to down-regulate
amygdala activation. Normally, a liter of fluid is generated daily,
carried from the nose to the back of the throat and swallowed.
Some of the mucus moves from the throat into the mouth and
mixes with saliva. Part of the increase in salivary OT following
nasal administration probably results from this direct movement
of mucus but it is unlikely that this would account for the increased
OT levels after 7 h. A mechanism parallel to sublingual or trans-
dermal administration of various medicines and other exogenous
substances seems more plausible (as suggested by Huffmeijer et al.,
2012).
It remains to be shown how exactly intranasally administered
OT enters into the brain or starts to influence brain neural activity
along other pathways, and whether the effects are visible during
at least 7 h not only in saliva but also in pertinent brain areas.
The feed forward mechanism of the oxytonergic system, leading
to more production of oxytocin with increased OT levels, may
play an important role in the explanation of the persistently high
OT levels. In natural circumstances, human lactation has been
suggested to be subject to such a feed forward mechanism (Weis-
man et al., 2012), comparable to the Ferguson reflex, in which
OT induced stimulation of the uterus facilitates the subsequent
release of OT (Churchland and Winkielman, 2012). More warm
physical contact has been shown to lead to higher OT levels in
a linear fashion (Feldman et al., 2012), and a similar feed for-
ward spiral of oxytocin levels may follow mutually reinforcing
cooperation among individuals belonging to the same in-group
(De Dreu, 2012). In rats, multiple oxytocin treatments have been
shown to be more effective after each OT administration (Moberg,
2003). The feed forward mechanism of the oxytonergic system may
lead to a self-perpetuating, elevated OT level after a first boost of
intranasal OT, and in that way treatment with exogenous oxy-
tocin may stimulate the “feed forward” release of the endogenous
peptide. Nevertheless, basic research on the neurobiological path-
way of intranasal oxytocin to pertinent parts of the brain is badly
needed (Churchland and Winkielman, 2012).
The lack of a significant difference in salivary OT level between
the 16 and 24 IU doses seems to indicate that the same concentra-
tion of the peptide was absorbed. The reason for slightly higher
initial amounts of salivary OT in the 16 IU dose condition might
be that the 16 IU dose saturates nasopharyngeal absorption result-
ing in maximal feed forward signaling, whereas higher doses might
cause sub-maximal feed forward signaling. Spray volume may also
have played a role, since 16 and 24 IU doses were administered as
different volumes. A larger volume may result in more swallowing
of the drug and thus lower availability for absorption (and less
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FIGURE 1 | Salivary oxytocin levels over the day in placebo (A,B) and after Administration of 16 or 24 IU oxytocin (B). Oxytocin or placebo was
administered through nasal spray directly after the baseline assessment; subsequent assessments every hour after administration of oxytocin or placebo.
feed forward signaling). It should be noted that in a recent study
Cardoso et al. (2012) found stronger effects of 24 IU of intranasal
oxytocin on the cortisol response to vigorous exercise compared
to a larger dose of 48 IU. For the dosage of oxytocin sniffs it is quite
possible that “less is more,” but as noted before (e.g., Churchland
and Winkielman, 2012) more research is needed to address the
issue of optimal amounts of OT and the scheduling of the sniffs
over time.
We assessed salivary OT at seven time points during the day
with 1 h intervals. Because OT levels had not returned to baseline
levels after 7 h, in future research assessments should cover a longer
period of time, preferably including the night (as has been done
for the diurnal curve of plasma OT levels, Forsling et al., 1998).
The diurnal pattern of OT levels in plasma shows a peak around
2:00 a.m. with a sharp decrease during the second half of the night
and an almost flat pattern during the day. Future studies should
examine this pattern with salivary OT levels in placebo as well as
in OT administration conditions in order to know at what point
in time the effects of intranasal administration of OT fade out and
when OT levels get back into the regular diurnal pattern.
Frontiers in Neuroscience | Neuroendocrine Science December 2012 | Volume 6 | Article 174 | 4
van IJzendoorn et al. Increased salivary OT after 7 h
Increased levels of oxytocin until at least 7 h after the
administration present possibilities for designing experiments on
the impact of oxytocin administration on cognitive functions,
emotions, and social behavior over longer periods of time. More
empirical evidence is needed to determine whether the increased
salivary OT levels also translate to measurable neurophysiological
changes over time. Intranasal oxytocin administration is increas-
ingly used in clinical trials on a variety of psychiatric disorders
(Meyer-Lindenberg et al., 2011) and in some cases the long-term
effects of a single dose seem promising. At the same time stud-
ies on the long-term consequences of oxytocin administration
may also clarify emerging ethical questions involved in the use
of oxytocin in brief experiments. Although MacDonald et al.
(2011) showed the absence of detrimental side-effects of various
amounts of oxytocin administered in a large number of experi-
ments on clinical and non-clinical samples, it remains to be seen
whether the positive behavioral effects of oxytocin on donating
and other forms of (parochial) altruism persist across a longer
period of time and affect interactions in the natural setting out-
side the laboratory. For some subjects these“positive”effects might
be unwanted and they may have to be informed before giving
consent.
In conclusion, we found that a single intranasal administration
of OT induces elevated levels of salivary OT up to 7 h after OT
administration, way beyond the period of a few hours in which
neurobehavioral effects of OT are commonly observed in psy-
chopharmacological studies. Because we do not know whether
the prolonged elevation of OT levels leads to long-term changes
in brain activation, cognition, and behavior, our findings raise
ethical questions about the use of intranasally administered OT
without provisions for the aftercare of the participants involved in
OT experiments.
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